MedTrace Logo

CtDNA Based MRD Testing for NAC Monitoring in TNBC

NCT06230185 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 422

Last updated 2025-01-07

No results posted yet for this study

Summary

A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.

Conditions

  • TNBC - Triple-Negative Breast Cancer
  • Minimal Residual Disease

Sponsors & Collaborators

  • Personalis Inc.

    lead INDUSTRY

Principal Investigators

  • Pavani Chalasani · George Washington University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-09
Primary Completion
2025-08-30
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06230185 on ClinicalTrials.gov